Finance and funding: latest news

Finance and funding features

Finance and funding news from aidsmap

More news

Finance and funding news selected from other sources

  • Bob Geldof slams wealthy countries over 'disgraceful' lack of HIV funding

    The Live Aid founder said there had been incredible advances in the fight against HIV and AIDS in the past 30 years, but that final steps were the most crucial.

    24 July 2014 | ABC News
  • AIDS 2014: Financing the new global HIV treatment vision – advocacy and economics

    The USAID- and PEPFAR-funded Health Policy Project’s own estimates of the global costs of reaching extremely high levels of ART coverage in low and middle-income countries suggest that between U.S.$5.5 to $9 billion might be required annually to meet this goal by 2020.

    24 July 2014 | Science Speaks
  • Funding for HIV prevention for people who inject drugs is in crisis, experts warn

    Harm Reduction International, the International Drug Policy Consortium and the International HIV/Aids Alliance will publish a report that confirms HIV prevention services for drug injectors are losing out due to "changing donor policies and national government neglect".

    20 July 2014 | The Observer
  • Declining investment could slow research and rollout of new HIV prevention options

    Investment in HIV prevention research fell US$50 million, or 4 percent, to US$1.26 billion in 2013, due to declining investments by the United States and European government donors, changes in the international development landscape and changes in the pipeline of HIV prevention products in various stages of development and implementation, according to a new report from the HIV Vaccines and Microbicides Resource Tracking Working Group.

    20 July 2014 | HIV Vaccines and Microbicides Resource Tracking Working Group press release
  • Kaiser/UNAIDS Study Finds Dip in Donor Government Commitments for AIDS In 2013

    Donor governments in 2013 committed US$8.1 billion in new funding to support the AIDS response in low- and middle-income countries, down 3 percent from 2012, finds a new report from the Kaiser Family Foundation and the Joint United Nations Programme on HIV/AIDS (UNAIDS) released in advance of the 2014 International AIDS Conference.

    19 July 2014 | Kaiser Family Foundation
  • Why HIV Drug Costs Are Spiking Under Obamacare

    Since the start of this year, many people with HIV have seen the out-of-pocket costs of their medications skyrocket. And advocates argue it’s not just price-gouging, but a blatant attempt by insurance companies to discriminate against patients who need expensive treatments.

    17 July 2014 | Buzzfeed
  • Complaint Says Insurance Plans Discriminate Against HIV Patients

    Four Florida insurers allegedly discriminate against people with HIV/AIDS by structuring their prescription drug benefits so that patients are discouraged from enrolling, according to a complaint filed by health advocacy groups.

    09 July 2014 | NPR
  • HIV interventions will not reach those who need them without increased efficiencies, review says

    While noting that HIV service delivery can’t be increased to needed levels with reduced resources, authors of a systematic review published in the July World Health Organization Bulletin say more efficient use of existing resources will be critical to making meaningful reductions in prevalence and infection rates.

    04 July 2014 | Science Speaks
  • Too soon for rich countries to stop HIV funding in poor ones

    The international community expects governments of low- and middle-income countries to invest more funds in their HIV responses, and to move towards fully domestically financed responses. But the political, social, economic and infrastructural factors in many low- and middle-income countries preclude domestic leadership for comprehensive HIV responses.

    04 July 2014 | The Conversation
  • New ARV prescribing guidelines for London (2014)

    The guidelines are the result of a therapeutic tender, which encourages drug manufacturers to offer volume discounts for different stages of the treatment pathway, for example, for preferred use in first-line, second-line and multiple resistant treatment.

    01 July 2014 | HIV i-Base
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.